Insight Molecular Diagnostics Inc. (IMDX)

From the record

Insight Molecular Diagnostics Inc.'s filings since 2017 show 12 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 6 times, the latest 2024-07-12); an auditor change (8-K item 4.01, 4 times, the latest 2025-04-17); a late-report notice (Form NT 10-K or NT 10-Q, 2 times, the latest 2024-04-01) (its current reports).

From the record

Insight Molecular Diagnostics Inc.'s 6 filed years say what it did: revenue went from $1 million in fiscal 2020 to $4 million in fiscal 2025, up 27.2% a year; it rose in 4 of 5 years; the deepest fall was 56% from fiscal 2021 to fiscal 2022; net income was positive in 0 of 5 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Insight Molecular Diagnostics Inc.'s shareholders' equity was below zero, so the profit on it is not read, and gross profitability: its products earned about 9 cents per dollar of everything the company owns. Leverage: it owed about 222 cents per dollar of assets, and net share issuance: its share count grew 133.2% over the year (the filed statements).

From the record

Insight Molecular Diagnostics Inc.'s standing among 17 graded names in its industry family: revenue of $4 million in fiscal 2025 ranks in the bottom 32% by size; a net margin of -1238.5% ranks in the bottom 26%; revenue growth of 61.7% a year over the last 3 filed years ranks in the top 16% (its annual reports).

From the record

Insight Molecular Diagnostics Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Riggs, Josh (CEO and President, as filed), filing under that title since 2022-12-09, 3.9 years (top 46% of its family); the 6 officers and directors filing in the last fifteen months have been on the record a median of 4 years (bottom 39%); 8 officer or director changes were reported on Form 8-K since 2023-11-13, against the 6 people in charge now (bottom 3%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Insight Molecular Diagnostics Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $12 million against no long-term debt tagged leaves 45% of its assets as net cash, top 19% of its family; cash from operations less capital spending is -625.6% of revenue (bottom 28%); a gross margin of 56.7% (top 46%); research spending of 392.1% of revenue (top 34%) (its annual report).

From the record

Insight Molecular Diagnostics Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 61.7% a year over the last three filed years against 27.2% over all 6, speeding up (top 10% of its family); the newest year grew 115.7% (top 3%); research spending grew 29.6% a year (top 21%); capital spending grew -9.8% a year (top 43%) (its annual reports). Insight Molecular Diagnostics Inc. reported 2 product lines in fiscal 2025: Laboratory Services at $4 million (99%), Kitted Products at $24 thousand (1%); 1 of 1 grew against the year before (its annual report).

From the record

Insight Molecular Diagnostics Inc.'s newest year against its own record: revenue of $4 million in fiscal 2025 came in 53.9% above the $3 million its prior three years' pace pointed to (top 10% of its family); net income of $50 million against a prior three-year average of $54 million (bottom 41%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 16%) (its annual reports).